Compare 10X Genomics Inc (TXG) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Williams-Sonoma, Inc. — how do they compare? 10X Genomics Inc trades at $67.59 (market cap $8.77B), while Williams-Sonoma, Inc. trades at $228.08 (market cap $26.80B). The key difference: Williams-Sonoma, Inc. is far larger — about 3.1× 10X Genomics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.34% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | WSM | |
|---|---|---|
Market Cap | $8.77B | $26.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $67.29 | $251.81 |
52-Week Low | $11.34 | $168.64 |
Enterprise Value | $8.29B | $27.30B |
Dividend Yield | — | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.
Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.
Williams-Sonoma (WSM) trades at $227.83, up 0.18% with a bearish technical signal despite strong fundamentals. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.10 beating expectations of $2.08. Revenue trends show stabilization around $7.7-8.0B with improving net margins to 14.73%. Technical indicators show the stock testing support at $225 with RSI at oversold levels, suggesting potential near-term bounce.
The outlook remains positive with analyst consensus target of $252.23 representing 10.7% upside. Strong market share gains in home furnishings and raised full-year guidance support bullish case, though tariff pressures and competitive retail environment present ongoing risks. Institutional buying activity, including HSBC's 12.1% position increase, reinforces confidence in the company's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
